NeurologyLive® Friday 5 — December 9, 2022

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: The Advantages of Multidisciplinary Care and APP Incorporation in Epilepsy

In a conversation with NeurologyLive^®, Lucretia Long, APRN-CNP, an associate clinical professor of neurology at OSU Wexner Medical Center, offered her perspective on the benefits of having multiple specialists available to provide comprehensive care to patients.

2: Peers & Perspectives: Assessing Response to Insomnia Treatment

In episode 10 of the NeurologyLive^® series, "Advanced Practice Providers’ Perspectives on Sleep Disorders: Impact of Insomnia on Patient Health," advanced practice practitioners discuss how they assess treatment response and patient adherence in insomnia, and considerations for changing treatment. [WATCH TIME: 8 minutes]

3: NeuroVoices: Sube Banerjee, MD, MSc, MBA, FRCPsych, on Replacing Traditional Noneffective Agents for Alzheimer Agitation

In the latest edition of our in-depth Q&A series, the professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the SYMBAD trial, and eliminating the use of mirtazapine and carbamazepine as medications to treat Alzheimer agitation.

4: Peer Exchange: Brain Health in Multiple Sclerosis

In episode 5 of the NeurologyLive^® series, "Challenges and Solutions in the Management of Multiple Sclerosis," an expert panel talks about the preservation of brain health regarding the use of sphingosine 1-phosphate receptor modulators to treat multiple sclerosis. [WATCH TIME: 10 minutes]

5: Working Towards Lowering ARIA Rates, Reducing Amyloid Plaques: Marwan Sabbagh, MD, FAAN

In a conversation with NeurologyLive^®, the behavioral neurologist at the Barrow Neurological Institute detailed the significance of low rates of ARIA found in lecanemab, and the direction of anti-amyloid therapies in the future. [WATCH TIME: 4 minutes]

—————————————————